Last €120.21 EUR
Change Today +1.53 / 1.29%
Volume 0.0
XP2 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:08 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

8510 Colonnade Center Drive

Raleigh, NC 27615

United States

Phone: 919-862-1000

Fax: 919-862-1095

rrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. In connection with the company’s purchase from Merck of the U.S. prescription pharmaceutical product rights to Pepcid Oral Suspension, it also purchased the U.S. prescription pharmaceutical product rights to Diuril Oral Suspension. Colazal (balsalazide disodium) Capsules Colazal is approved by the FDA for the treatment of mildly to moderately active UC. The FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with UC. Santarus Products Uceris (budesonide) Extended Release Tablets Uceris is a locally acting corticosteroid in a once-daily oral tablet formulation that utilizes proprietary multimatrix system (MMX) colonic delivery technology. Uceris is indicated for the induction of remission in patients with active, mild to moderate UC. Santarus received FDA approval of Uceris in January 2013 and launched this product commercially in February 2013. There are four patents that the company provides coverage for Uceris, with expiration dates in 2020. There are also pending applications that if issued would provide further protection until 2031 and 2033. Zegerid (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension Zegerid is an immediate-release formulation of the proton pump inhibitor omeprazole and is indicated for short-term treatment of active duodenal ulcer, short-term treatment of active benign gastric ulcer, treatment of GERD, maintenance of healing of erosive esophagitis and reduction of risk of upper gastrointestinal bleeding in critically ill patients. Glumetza (metformin hydrochloride) Extended Release Tablets Glumetza is a once-daily, extended-release formulation of metformin in 500 mg and 1000 mg dosage strengths that incorporates patented drug delivery technology and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Metformin is one of the most commonly prescribed oral medications for the treatment of type 2 diabetes. There are four patents for Glumetza 500 mg dose product, with expiration dates in 2016, 2020 and 2021. There are three patents for Glumetza 1000 mg dose product, with expiration dates in 2020 and 2025. There are also pending applications that if issued would provide further protection until 2025. Cycloset (bromocriptine mesylate) Tablets Cycloset (bromocriptine mesylate) 0.8 mg tablets is a novel formulation of bromocriptine, and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes both as mono-therapy and in combination with other oral antidiabetic agents. There are eight patents that Santarus licensed from S2 and VeroScience that the company provides coverage for Cycloset, with expiration dates in 2014, 2015, 2023 and 2032. Fenoglide (fenofibrate) Tablets Fenoglide (fenofibrate) 40 mg and 120 mg tablets is a proprietary formulation of fenofibrate and is indicated as an adjunct to diet to reduce elevated LDL-C, total cholesterol, triglycerides and Apo B, and to increase HDL-C, in adult patients with primary hyperlipidemia or mixed dyslipidemia. Fenoglide also is indicated as an adjunct to diet for treatment of adult patients with hypertriglyceridemia. There are three patents that the company provides coverage for the Fenoglide products, with expiration dates in 2024. There are also pending applications that if issued would provide further protection until 2024. Development Programs Xifaxan (rifaximin) Tablets The company completed two identical pivotal Phase 3 trials to evaluate the efficacy and safety of rifaximin 550 mg dosed three times a day in the treatment of non-constipation IBS. Relistor (methylnaltrexone bromide) The company has two development programs for methylnaltrexone bromide, such as for OIC in patients with chronic non-malignant pain administered through SI (OIC Chronic Pain); and for OIC in patients with chronic non-malignant pain administered orally (OIC Oral). OIC Chronic Pain: The company announced that the FDA accepted for filing its sNDA for Relistor (methylnaltrexone bromide) SI to treat

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €120.21 EUR +1.53

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $44.73 USD +0.25
Cubist Pharmaceuticals Inc $69.03 USD +0.12
Jazz Pharmaceuticals PLC $162.92 USD +0.21
Lupin Ltd 1,285 INR -4.25
Santen Pharmaceutical Co Ltd ¥6,000 JPY -110.00
View Industry Companies
 

Industry Analysis

XP2

Industry Average

Valuation XP2 Industry Range
Price/Earnings 100.0x
Price/Sales 8.0x
Price/Book 13.7x
Price/Cash Flow 53.0x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.